Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies. Show more

Location: | Website: geminitherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$58.00

Open

$57.10

Volume

275,330

Day Range

$56.22 - $57.72

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.25%

Institutional Own.

87.53%

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date